|Drug Patent Number||Company||Drug Patent Title||Drug Patent Expiry||Activity Alert|
|These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).|
|US8685443||PFIZER||Sequestering subunit and related compositions and methods|| |
(1 year, 9 months from now)
|US7815934||PFIZER||Sequestering subunit and related compositions and methods|| |
(4 years from now)
Troxyca Er is owned by Pfizer.
Troxyca Er contains Naltrexone Hydrochloride; Oxycodone Hydrochloride.
Troxyca Er has a total of 2 drug patents out of which 0 drug patents have expired.
Troxyca Er was authorised for market use on 19 August, 2016.
Troxyca Er is available in capsule, extended release;oral dosage forms.
Troxyca Er can be used as management of pain severe enough to require daily, around-the-clock, long term opioid treatment by orally administering a plurality of composite subunits as claimed.
The generics of Troxyca Er are possible to be released after 12 December, 2027.
Market Authorisation Date: 19 August, 2016
Treatment: Management of pain severe enough to require daily, around-the-clock, long term opioid treatment by orally administering a plurality of composite subunits as claimed
Dosage: CAPSULE, EXTENDED RELEASE;ORAL
900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight
Join them to stay ahead in capturing the next drug going generic